We hypothesized that gBRCA1/BRCA2 carriers developing breast or ovarian cancer might be at higher risk for developing chemotherapy-related acute hematologic toxicity and therapy-related myeloid neoplasms. The gene discussed is BRCA2; the disease is ovarian carcinoma.